Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Completed · Phase 2 · NCT02997761
Conditions: Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
At a glance
- Research payments reported, 2025
- $15,089
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 19
About the trial
- Sponsor
- University of California, Davis (with National Cancer Institute (NCI), Pharmacyclics LLC.)
- Tested
- Blinatumomab (biological), Ibrutinib (drug)
- Dates
- Started 2017-06-27; completion 2025-07-17
- Results posted
- Yes
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.
From ClinicalTrials.gov, last updated 2026-06-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $15,089 in research payments for this study in 2025 (1 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.